FOLH1 and neoplasm: The addition of PSMA PET/CT in the work-up of PCa during AS can lead to the performance of an additional biopsy due to the appearance of new tracer-avid lesions or due to an elevation of SUVmax values, resulting in an upgrade of the neoplasm risk class.